Ultrashort gonadotropin-releasing hormone agonist combined with flexible multidose gonadotropin-releasing hormone antagonist for poor responders in in vitro fertilization/embryo transfer programs

Fertil Steril. 2008 Jul;90(1):228-30. doi: 10.1016/j.fertnstert.2007.06.022. Epub 2007 Aug 6.

Abstract

To evaluate the appropriate controlled ovarian hyperstimulation (COH) protocol in poor responders, we compared the stimulation characteristics of 21 cycles, which included the ultrashort gonadotropin-releasing hormone (GnRH) agonist combined with the flexible multidose GnRH antagonist, to the patients' previous failed in vitro fertilization attempts. The use of an ultrashort GnRH-agonist/GnRH-antagonist COH protocol resulted in a statistically significantly greater number of follicles larger than 14 mm on the day of hCG administration, a higher number of oocytes retrieved and embryos transferred, and a reasonable clinical pregnancy rate (14.3%).

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Chorionic Gonadotropin / administration & dosage
  • Drug Administration Schedule
  • Embryo Transfer*
  • Female
  • Fertility Agents, Female / administration & dosage*
  • Fertilization in Vitro*
  • Gonadotropin-Releasing Hormone / administration & dosage
  • Gonadotropin-Releasing Hormone / agonists
  • Gonadotropin-Releasing Hormone / analogs & derivatives*
  • Gonadotropin-Releasing Hormone / antagonists & inhibitors
  • Hormone Antagonists / administration & dosage*
  • Humans
  • Oocyte Retrieval
  • Ovulation Induction / methods*
  • Pregnancy
  • Pregnancy Rate
  • Sperm Injections, Intracytoplasmic
  • Treatment Failure
  • Treatment Outcome
  • Triptorelin Pamoate / administration & dosage*

Substances

  • Chorionic Gonadotropin
  • Fertility Agents, Female
  • Hormone Antagonists
  • Triptorelin Pamoate
  • Gonadotropin-Releasing Hormone
  • cetrorelix